Lowest Glucagon/Highest C-Peptide in Oral Glucose Tolerance Test: Clinical Utility in Monitoring Glucose Control in Type 2 Diabetes Mellitus
DOI: https://doi.org/10.2147/dmso.s459392
2024-04-18
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Lina Chang, &ast Xiaohui Ma, &ast Menghua Yuan, &ast Li Ding, Yian Gu, Lili Liu, Yan Li, Hua Shu, Ming Liu, Qing He Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qing He; Ming Liu, Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China, Email ; Purpose: Understanding factors that influence blood glucose levels in patients with type 2 diabetes mellitus (T2DM) is crucial for managing hyperglycemia. Currently, there is no standardized interpretation method for glucagon levels in oral glucose tolerance test (OGTT). This study aims to assess the relationship between the lowest glucagon/highest C-peptide ratio (Lglc/Hcp) in OGTT and glucose control levels in T2DM. Patients and Methods: Clinical data from 120 patients with T2DM were examined to compare the correlations of Lglc/Hcp and other pancreatic islet function-associated indices with fasting blood glucose (G0), glucose at 120 minutes in OGTT (G120), hemoglobin A1c (HbA1c), and the area under the glucose curve in OGTT (AUCglu). Additionally, the study investigated difference in Lglc/Hcp between patient groups based on the highest blood glucose levels (Hglu) in OGTT (Hglu ≥ 16.7 mmol/L vs Hglu < 16.7 mmol/L). Results: The generalized linear model suggested that Lglc/Hcp significantly correlated with G0 (B = 0.85, P < 0.001), G120(B = 1.46, P < 0.001), HbA1c (B = 0.67, P < 0.001), and AUCglu (B = 3.46, P < 0.001). This correlation surpassed C-peptide and glucagon-related parameters, even after adjusting for confounding factors. Furthermore, Lglc/Hcp was notably higher in patients with Hglu ≥ 16.7 mmol/L compared to those with Hglu < 16.7 mmol/L (Z = − 3.71, p < 0.001). Conclusion: Lglc/Hcp in OGTT closely relates to blood glucose control in patients with T2DM, potentially reflecting the overall pancreatic islet function in regulating glucose levels. Moreover, inhibiting glucagon secretion may be a crucial consideration for patients requiring insulin treatment. Keywords: C-peptide, glucose control, glucagon, type 2 diabetes mellitus Graphical Unger first assumed that an increase in glucagon is necessary for the occurrence of diabetes, 1 diverging from the conventional insulin-centric model of type 2 diabetes (T2DM) pathogenesis into the dual hormone hypothesis. However, the precise measurement of glucagon poses challenges due to its low concentration and the presence of similar peptide compounds in the blood. 2 Notably, Mercodia developed sandwich ELISA kits using two antibodies to improve sensitivity and specificity. 3 Furthermore, glucagon is inherently unstable and susceptible to degradation, posing an additional hurdle in the accurate assessment of its levels in clinical settings. 4 In this research, we added enzyme inhibitors into blood collection vessels to impede glucagon degradation and ensure its stability. In the past, numerous studies have examined the evolving pattern of glucagon levels across the spectrum from normal glucose tolerance to prediabetes and diabetes, 5–7 however, there is no unified standard on how to interpret the glucagon level in the oral glucose tolerance test (OGTT) of patients with T2DM. Notably, direct analysis using glucagon levels does not appear to demonstrate a significant association with glucose regulation. Research by Hosokawa revealed that in individuals with type 2 diabetes, irrespective of whether they were administered DPP-4 inhibitors or GLP-1 analogues, glucagon levels did not show a substantial correlation with glucose levels, moreover, a study by Kumpatla indicated that fasting glucagon was not linked to blood glucose or glycosylated hemoglobin. 5,8 Subsequent investigations, upon realizing the lack of correlation between absolute glucagon levels and blood glucose, explored its connection with blood glucose through variations in glucagon at 30 minutes or the glucagon-to-insulin ratio, yet the findings were inconsistent. 5,9–12 Taking into account the response of pancreatic B cells, which increase insulin release, and pancreatic A cells, which reduce glucagon secretion following oral glucose intake to sustain stable blood glucose levels, and acknowledging that some patients had received insulin therapy prior to the OGTT, we employed the ratio of the lowest glucagon to highest C-peptide (Lglc/Hcp) during the OGTT. In this cross-sectional observational study, our primary aim was to assess the association between Lglc/Hcp and blood glucose control lev -Abstract Truncated-
endocrinology & metabolism